Natera (NTRA) - Stock Price & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6323071042
Natera, Inc. is a global diagnostics company specializing in molecular testing services. The company offers a diverse range of products tailored for various medical needs.
One of Natera's flagship products is Panorama, a non-invasive prenatal test designed to screen for chromosomal abnormalities in fetuses, particularly in twin pregnancies. Horizon carrier screening is another key product that identifies genetic variations in individuals and couples that could lead to specific genetic conditions.
Vistara single-gene NIPT is a screening test focusing on 25 single-gene disorders responsible for severe skeletal, cardiac, and neurological conditions. Spectrum provides preimplantation genetic tests for couples undergoing IVF, while Anora aids in analyzing miscarriage tissue.
Empower is Natera's hereditary cancer screening test, and the company also offers a non-invasive prenatal paternity product for couples to establish paternity pre-birth.
Furthermore, Natera's innovative products include Signatera, a ctDNA blood test for disease monitoring in cancer patients, Altera comprehensive genomic profiling for tissue-based analysis, and Prospera for assessing rejection in kidney transplant patients.
The company's offerings extend to Renasight, a kidney gene panel test, and Constellation, a cloud-based software for laboratory customers to access advanced algorithms and bioinformatics.
Natera reaches its customers through a combination of direct sales and partnerships with laboratory and distribution channels. It collaborates with industry leaders like BGI Genomics Co., Ltd. and Foundation Medicine, Inc., to advance genetic testing technology and personalized monitoring solutions.
Founded in 2003, Natera is headquartered in Austin, Texas, and continues to innovate in the field of molecular diagnostics. For more information, visit their website at https://www.natera.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
NTRA Stock Overview
Market Cap in USD | 10,816m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2015-07-02 |
NTRA Stock Ratings
Fundamental | -4.55 |
Dividend | - |
Growth 5y | 5.23 |
Rel. Performance vs Sector | 2.57 |
Analysts | 4.41/5 |
Fair Price Momentum | 91.88 USD |
Fair Price DCF | - |
NTRA Dividends
Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
NTRA Growth Ratios
Growth 12m | 68.56% |
Growth Correlation 12m | 43% |
Growth Correlation 3m | 83% |
CAGR 5y | 34.82% |
Sharpe Ratio 12m | 1.32 |
Alpha vs SP500 12m | 26.29 |
Beta vs SP500 5y weekly | 1.41 |
ValueRay RSI | 72.19 |
Volatility GJR Garch 1y | 46.04% |
Price / SMA 50 | 17.38% |
Price / SMA 200 | 57.55% |
Current Volume | 971.3k |
Average Volume 20d | 1638.3k |
External Links for NTRA Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of March 29, 2024, the stock is trading at USD 91.46 with a total of 971,264 shares traded.
Over the past week, the price has changed by -0.45%, over one month by +19.48%, over three months by +47.42% and over the past year by +68.90%.
According to ValueRays Forecast Model, NTRA Natera will be worth about 103.3 in March 2025. The stock is currently trading at 91.46. This means that the stock has a potential upside of +12.9%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 93.3 | 2.04% |
Analysts Target Price | 71.2 | -22.2% |
ValueRay Target Price | 103.3 | 12.9% |